peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Hansa Biopharma to host conference call to provide interim results for January-September 2021 and Business Update

7 Oct 2021, 08:00

Lund, Sweden October 7, 2021 Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will publish its interim report for January-September 2021 at 8:00 CET on October 21, 2021. All interested parties are invited to participate in a telephone conference, which will include a presentation of the interim results and a business update, on the same date at 14:00 CET/8:00am EST. The event will be hosted by Hansa Biopharma’s CEO, Søren Tulstrup, and CFO, Donato Spota, and the presentation will be held in English.

Slides used in the presentation will be live on the company website during the call under “Events & Webcast,” and will also be made available online after the call. Link to presentation

To participate in the telephone conference, please use the dial-in details provided below:

Sweden: +46 856 64 27 07

United Kingdom: +44 333 300 92 74

United States: +1 646 722 49 04

The webcast will be available on

Updated Calendar and Events 2021/2022

Oct 21, 2021                 Interim report for Jan-Sep 2021

Oct 22+26, 2021           Kempen NDRS EU/US (virtual)

Nov 10, 2021                Ökonomisk Ugebrev Life Science Conf., Copenhagen

Nov 11, 2021                Redeye Life Science Day 2021, Stockholm

Nov 16-18, 2021           Jefferies Global Healthcare Conference, London/virtual

Nov 25, 2021                Erik Penser Banks Bolagsdag, Stockholm/virtual

Dec 1-2, 2021               Geneva European MidCap event

Jan 9-13, 2021             JPM Week, San Francisco

Jan 10-13, 2021            HC Wainwright BioConnect (virtual)

Feb 3, 2022                  Year-End report for Jan - Dec 2021

Mar 15, 2022                Carnegie Healthcare Seminar 2022, Stockholm

For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma 
Mobile: +46 (0) 709-298 269

Katja Margell
Head of Corporate Communications 
Hansa Biopharma 
Mobile: +46 (0) 768-198 326

About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program, based on the Company’s proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at